LONDON, Sept 30 (Reuters) - British pharmaceutical firmGlaxoSmithKline (GSK) said on Monday it agreed to sell itsthrombosis treatment brands and related manufacturing facilityto South Africa's Aspen for 700 million pounds ($1.13billion).
The company said the divestment, which will earn it proceedsof 600 million pounds, was part of its stragtegy to focus onproducts with the most growth potential.
GSK owns an 18.6 percent stake in Aspen, South Africa'sbiggest generic drug maker.